<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="793" width="595">
	<fontspec id="0" size="9" family="JALMJF+AdvMinionNormal_Rm" color="#000000"/>
	<fontspec id="1" size="9" family="JALMKH+AdvMinionNormal_It" color="#000000"/>
	<fontspec id="2" size="9" family="JALMGP+AdvMacMthSyN" color="#000000"/>
	<fontspec id="3" size="10" family="JALMGM+AdvUvcb" color="#000000"/>
	<fontspec id="4" size="9" family="JALMIE+AdvMPi-One" color="#000000"/>
	<fontspec id="5" size="9" family="JALNBG+AdvEls-ent5" color="#000000"/>
	<fontspec id="6" size="9" family="JALNFH+AdvEls-ent4" color="#000000"/>
	<fontspec id="7" size="8" family="JALMGO+AdvUvc" color="#000000"/>
	<fontspec id="8" size="8" family="JALMIB+AdvUvcdo" color="#000000"/>
	<fontspec id="9" size="8" family="JALMGP+AdvMacMthSyN" color="#000000"/>
	<fontspec id="10" size="11" family="JALMGM+AdvUvcb" color="#000000"/>
	<fontspec id="11" size="7" family="JALMJF+AdvMinionNormal_Rm" color="#000000"/>
<text top="238" left="53" width="130" height="9" font="0">from ECACC), for an orangutan (</text>
<text top="238" left="182" width="59" height="9" font="1">Pongo pygmaeus</text>
<text top="238" left="241" width="51" height="9" font="0">; primary cell</text>
<text top="249" left="53" width="239" height="9" font="0">line AG12256, purchased from ECACC) and for 11 western</text>
<text top="260" left="53" width="51" height="9" font="0">chimpanzees (</text>
<text top="260" left="104" width="73" height="9" font="1">Pan troglodytes verus</text>
<text top="260" left="176" width="116" height="9" font="0">) using identical PCR setup as in</text>
<text top="271" left="53" width="239" height="9" font="0">human genotyping. DNA sample of one chimpanzee originates</text>
<text top="281" left="53" width="239" height="9" font="0">from a wild-born male specimen (Pino) from Tallinn Zoo, Estonia.</text>
<text top="292" left="53" width="239" height="9" font="0">Ten samples of wild-caught and unrelated animals (Annaclara,</text>
<text top="303" left="53" width="239" height="9" font="0">Frits, Hilko, Louise, Marco, Oscar, Regina, Socrates, Sonja, and</text>
<text top="314" left="53" width="239" height="9" font="0">Yoran) are from the collection stored at the Max Planck Institute</text>
<text top="325" left="53" width="239" height="9" font="0">for Evolutionary Anthropology, Leipzig, Germany, and were kindly</text>
<text top="336" left="53" width="239" height="9" font="0">shared by Dr. Svante Pa¨a¨bo. This sample collection is described in</text>
<text top="347" left="53" width="203" height="9" font="0">detail elsewhere [Becquet et al., 2007; Ptak et al., 2004].</text>
<text top="358" left="62" width="205" height="9" font="0">Ancestral sequence of the targeted genomic region (</text>
<text top="358" left="267" width="25" height="9" font="1">WNK1</text>
<text top="369" left="53" width="239" height="9" font="0">exon10–intron10–exon11) was assessed by the comparative</text>
<text top="380" left="53" width="145" height="9" font="0">sequencing of the genomic DNA from</text>
<text top="380" left="201" width="54" height="9" font="1">WNK1 AluYb8</text>
<text top="380" left="259" width="32" height="9" font="0">insertion</text>
<text top="391" left="53" width="45" height="9" font="0">noncarrier (</text>
<text top="391" left="97" width="7" height="8" font="2"></text>
<text top="391" left="104" width="3" height="9" font="0">/</text>
<text top="391" left="107" width="7" height="8" font="2"></text>
<text top="391" left="114" width="177" height="9" font="0">) and carrier (Alu/Alu) human homozygotes as</text>
<text top="402" left="53" width="239" height="9" font="0">well as from a chimpanzee (Pino). Sequencing primers are listed</text>
<text top="413" left="53" width="239" height="9" font="0">in Supp. Table S4. PCR cycling conditions, product purification,</text>
<text top="424" left="53" width="239" height="9" font="0">and sequencing have been described elsewhere [Hallast et al.,</text>
<text top="435" left="53" width="239" height="9" font="0">2005]. Sequences were aligned using Web-based global alignment</text>
<text top="446" left="53" width="239" height="9" font="0">program ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/). Human</text>
<text top="457" left="53" width="239" height="9" font="0">WNK1 alternative sequences of the region including exon 10/intron</text>
<text top="468" left="53" width="103" height="9" font="0">10/exon 11 (without and with</text>
<text top="468" left="158" width="25" height="9" font="1">AluYb8</text>
<text top="468" left="185" width="107" height="9" font="0">insertion) were compared with</text>
<text top="479" left="53" width="239" height="9" font="0">available genome sequences from multiple species using the BLAST</text>
<text top="490" left="53" width="239" height="9" font="0">tool blastn (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The searches</text>
<text top="501" left="53" width="239" height="9" font="0">were performed against the following sequence databases: NCBI</text>
<text top="512" left="53" width="239" height="9" font="0">Genomes, Whole-Genome-Shotgun Sequences. Nucleotide sub-</text>
<text top="523" left="53" width="239" height="9" font="0">stitution rates between human and chimpanzee were calculated as</text>
<text top="534" left="53" width="239" height="9" font="0">the percentage of the number of substitutions divided with the</text>
<text top="545" left="53" width="239" height="9" font="0">total number of aligned nucleotides in the specific genomic</text>
<text top="555" left="53" width="239" height="9" font="0">region. The number of substitutions and the total number of</text>
<text top="566" left="53" width="239" height="9" font="0">aligned nucleotides were calculated using EMBOSS stretcher</text>
<text top="577" left="53" width="187" height="9" font="0">(http://emboss.sourceforge.net/) [Rice et al., 2000].</text>
<text top="605" left="53" width="168" height="9" font="3">Stage 1 Association Analysis in HYPEST</text>
<text top="623" left="62" width="120" height="9" font="0">In Stage 1, the association of the</text>
<text top="623" left="184" width="53" height="9" font="1">WNK1 AluYb8</text>
<text top="623" left="241" width="51" height="9" font="0">insertion with</text>
<text top="634" left="53" width="239" height="9" font="0">BP was addressed using HYPEST (HYPertension in ESTonia)</text>
<text top="645" left="53" width="239" height="9" font="0">case–cohort sample collection (Table 1; recruitment details in</text>
<text top="656" left="53" width="239" height="9" font="0">Supp. Text S1). The HYPEST study has been approved by the</text>
<text top="667" left="53" width="239" height="9" font="0">Ethics Committee on Human Research of University of Tartu (no.</text>
<text top="678" left="53" width="239" height="9" font="0">122/13, 22.12.2003; 137/20, 25.04.2005) and it was carried out in</text>
<text top="689" left="53" width="239" height="9" font="0">compliance with the Helsinki Declaration. All the participants</text>
<text top="700" left="53" width="239" height="9" font="0">have given their written informed consent. HYPEST subjects were</text>
<text top="711" left="53" width="239" height="9" font="0">recruited across Estonia during 2004–2007 (1,823 individuals; age</text>
<text top="722" left="53" width="239" height="9" font="0">range: 18–85 years) with the aim to analyze genetic–epidemiological</text>
<text top="733" left="53" width="239" height="9" font="0">risk factors for essential hypertension and related cardiovascular</text>
<text top="744" left="53" width="239" height="9" font="0">disease in Estonian population. In the current study, the total</text>
<text top="238" left="304" width="169" height="9" font="0">number of genotyped HYPEST subjects was</text>
<text top="238" left="477" width="5" height="9" font="1">n</text>
<text top="238" left="483" width="7" height="8" font="4">5</text>
<text top="238" left="492" width="50" height="9" font="0">1,747. At the</text>
<text top="249" left="304" width="239" height="9" font="0">recruitment, the resting BP of each participant has been measured</text>
<text top="260" left="304" width="239" height="9" font="0">by trained clinicians using a standard mercury column sphygmo-</text>
<text top="271" left="304" width="239" height="9" font="0">manometer and size-adjusted cuffs. HYPEST individuals pos-</text>
<text top="281" left="304" width="239" height="9" font="0">sessed a documented history of multiple systolic and diastolic BP</text>
<text top="292" left="304" width="239" height="9" font="0">readings (on average, 4.31 readings per individual during mean</text>
<text top="303" left="304" width="239" height="9" font="0">3.17 years). For the analysis, the median across the longitudinal</text>
<text top="314" left="304" width="239" height="9" font="0">BP readings as well as the median of the subject’s age during the</text>
<text top="325" left="304" width="72" height="9" font="0">readings were used.</text>
<text top="336" left="313" width="230" height="9" font="0">Association analysis with SBP and DBP was performed using</text>
<text top="347" left="304" width="239" height="9" font="0">1,211 individuals (803 women, 408 men) derived from the</text>
<text top="358" left="304" width="239" height="9" font="0">population-based cohort across Estonia consisting of long-term</text>
<text top="369" left="304" width="239" height="9" font="0">blood donors not receiving any antihypertensive medication</text>
<text top="380" left="304" width="239" height="9" font="0">(Table 1). For binary analysis with essential hypertension, cases</text>
<text top="391" left="304" width="3" height="9" font="0">(</text>
<text top="391" left="307" width="5" height="9" font="1">n</text>
<text top="391" left="313" width="7" height="8" font="4">5</text>
<text top="391" left="322" width="221" height="9" font="0">673) were defined as untreated subjects with BP readings</text>
<text top="404" left="304" width="9" height="6" font="5">Z</text>
<text top="402" left="312" width="230" height="9" font="0">160/100 mmHg based on the median of several measurements or</text>
<text top="413" left="304" width="239" height="9" font="0">patients receiving antihypertensive therapy. Normotensive controls</text>
<text top="424" left="304" width="3" height="9" font="0">(</text>
<text top="424" left="307" width="5" height="9" font="1">n</text>
<text top="424" left="313" width="7" height="8" font="4">5</text>
<text top="424" left="322" width="32" height="9" font="0">601; SBP</text>
<text top="422" left="356" width="9" height="11" font="6">r</text>
<text top="424" left="365" width="59" height="9" font="0">140 mmHg/DBP</text>
<text top="422" left="426" width="9" height="11" font="6">r</text>
<text top="424" left="435" width="108" height="9" font="0">90 mmHg) were selected from</text>
<text top="435" left="304" width="239" height="9" font="0">the population-based HYPEST cohort among the subjects that</text>
<text top="446" left="304" width="200" height="9" font="0">have never been prescribed antihypertensive treatment.</text>
<text top="473" left="304" width="81" height="9" font="3">Stage 2 Replication</text>
<text top="492" left="313" width="137" height="9" font="0">In Stage 2, association testing of the</text>
<text top="492" left="453" width="54" height="9" font="1">WNK1 AluYb8</text>
<text top="492" left="510" width="32" height="9" font="0">insertion</text>
<text top="503" left="304" width="239" height="9" font="0">and BP was performed in two European samples—the BRIGHT</text>
<text top="514" left="304" width="239" height="9" font="0">(BRItish Genetics of HyperTension) and the CADCZ (Coronary</text>
<text top="525" left="304" width="239" height="9" font="0">Artery Disease in Czech)—and the results were combined in</text>
<text top="536" left="304" width="239" height="9" font="0">meta-analysis with Stage 1 study samples. The final sample size in</text>
<text top="547" left="304" width="239" height="9" font="0">meta-analysis with SBP and DBP was 3,494 subjects (2,088</text>
<text top="558" left="304" width="239" height="9" font="0">women, 1,406 men; none treated with antihypertensive medica-</text>
<text top="568" left="304" width="239" height="9" font="0">tion), and with hypertension 3,181 cases/2,720 controls (women,</text>
<text top="579" left="304" width="113" height="9" font="0">1,851/1,692; men 1,330/1,028).</text>
<text top="590" left="313" width="230" height="9" font="0">CADCZ study has been approved by the Ethics Committee of</text>
<text top="601" left="304" width="239" height="9" font="0">Charles University—First Faculty of Medicine (December 1996)</text>
<text top="612" left="304" width="239" height="9" font="0">and the BRIGHT study was approved by the Ethics Committee</text>
<text top="623" left="304" width="239" height="9" font="0">from local research committees of all partner institutes. All</text>
<text top="634" left="304" width="239" height="9" font="0">BRIGHT and CADCZ participants have given their written</text>
<text top="645" left="304" width="239" height="9" font="0">informed consent. The MRC British Genetics of Hypertension</text>
<text top="656" left="304" width="239" height="9" font="0">case–control samples have been recruited across the United</text>
<text top="667" left="304" width="239" height="9" font="0">Kingdom (http://www.brightstudy.ac.uk). Case ascertainment and</text>
<text top="678" left="304" width="239" height="9" font="0">phenotyping has been described elsewhere [Caulfield et al., 2003].</text>
<text top="689" left="304" width="239" height="9" font="0">Briefly, cases originated from severely hypertensive families (1,700</text>
<text top="700" left="304" width="239" height="9" font="0">sibpairs and 800 families collected for transmission disequilibrium</text>
<text top="711" left="304" width="239" height="9" font="0">test) were defined as patients under antihypertensive treatment</text>
<text top="722" left="304" width="83" height="9" font="0">and with BP readings</text>
<text top="724" left="391" width="9" height="6" font="5">Z</text>
<text top="722" left="400" width="143" height="9" font="0">150/100 mmHg based on one reading</text>
<text top="733" left="304" width="8" height="9" font="0">or</text>
<text top="734" left="318" width="9" height="6" font="5">Z</text>
<text top="733" left="327" width="216" height="9" font="0">145/95 mmHg based on the mean of three readings.</text>
<text top="744" left="304" width="122" height="9" font="0">Healthy normotensive controls (</text>
<text top="744" left="426" width="5" height="9" font="1">n</text>
<text top="744" left="432" width="7" height="8" font="4">5</text>
<text top="744" left="441" width="36" height="9" font="0">2,000; BP</text>
<text top="742" left="480" width="9" height="11" font="6">o</text>
<text top="744" left="489" width="54" height="9" font="0">140/90 mmHg,</text>
<text top="184" left="53" width="35" height="9" font="3">Figure 1.</text>
<text top="185" left="97" width="97" height="8" font="7">Detection of the presence of</text>
<text top="185" left="196" width="22" height="8" font="8">WNK1</text>
<text top="185" left="220" width="29" height="8" font="7">intron 10</text>
<text top="185" left="251" width="24" height="8" font="8">AluYb8</text>
<text top="185" left="277" width="195" height="8" font="7">insertion in primates. Agarose gel (3%) electrophoresis of</text>
<text top="185" left="474" width="22" height="8" font="8">WNK1</text>
<text top="185" left="497" width="45" height="8" font="7">intron 10 PCR</text>
<text top="194" left="53" width="490" height="8" font="7">products amplified from human, chimpanzee, gorilla, and orangutan genomic DNAs. In humans, alternative genotype carriers are shown: wild-</text>
<text top="203" left="53" width="85" height="8" font="7">type homozygote without</text>
<text top="203" left="140" width="24" height="8" font="8">AluYb8</text>
<text top="203" left="165" width="34" height="8" font="7">insertion (</text>
<text top="203" left="199" width="7" height="7" font="9"></text>
<text top="203" left="206" width="2" height="8" font="7">/</text>
<text top="203" left="208" width="7" height="7" font="9"></text>
<text top="203" left="215" width="133" height="8" font="7">, PCR product 353 bp); heterozygous (A/</text>
<text top="203" left="348" width="7" height="7" font="9"></text>
<text top="203" left="355" width="188" height="8" font="7">) and homozygous (A/A, PCR product 660 bp) carriers of</text>
<text top="212" left="53" width="43" height="8" font="7">the insertion</text>
<text top="763" left="53" width="15" height="10" font="10">808</text>
<text top="766" left="99" width="156" height="7" font="11">HUMAN MUTATION, Vol. 32, No. 7, 806–814, 2011</text>
</page>
</pdf2xml>
